» Articles » PMID: 35589884

Different Impact of Early and Late Stages Irreversible Eye Diseases on Vision-specific Quality of Life Domains

Overview
Journal Sci Rep
Specialty Science
Date 2022 May 19
PMID 35589884
Authors
Affiliations
Soon will be listed here.
Abstract

To determine the differential impact of the irreversible eye diseases on vision-related quality of life (VRQoL) in a multi-ethnic Asian population. 2652 participants from the Singapore Epidemiology of Eye Disease Study, with any of the following early and late-stage eye conditions including age-related macular degeneration (AMD, n = 158), diabetic retinopathy (DR, n = 105; non vision threatening [non-VTDR]; VTDR), glaucoma (n = 57) and myopic macular degeneration (MMD, n = 106), or none of the above (controls, 2226 [83.9%]) were included. Rasch-scaled scores of the Emotional well-being Mobility and Reading subscales of the Impact of Vision Impairment (IVI) questionnaire, collectively referred to as "VRQoL" were assessed. Multivariable linear regression analyses and pairwise comparisons adjusting for age, gender, ethnicity, socio-economic status, BMI, smoking, alcohol use, presence of systemic diseases and presenting VI were performed to assess and compare the impact of the presence and severity of each eye condition on the three IVI domains. Multivariable adjusted pairwise comparisons of VRQoL between early stages of the four eye diseases showed no significant differences (all P > 0.05). For late stage diseases, individuals with VTDR had significantly larger decrements in Emotional well-being compared to glaucoma (β - 0.81; 95% CI - 1.47 to - 0.16) and MMD (β - 1.17; 95% CI - 2.16 to - 0.18); and Reading decrements compared to glaucoma (β - 0.66; 95% CI - 1.22 to - 0.11). When compared to late glaucoma, individuals with late AMD (β - 0.76; 95% CI - 1.50 to - 0.01) had significantly larger IVI Mobility subscale decrements. VTDR and late AMD, appear to have the greatest impact on VRQoL, compared to late glaucoma and MMD, suggesting a differential impact of late-stage eye disease categorization on VRQoL.

Citing Articles

Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision.

Nicolescu M, Haussler V, Paul F, Oertel F, Schindler P, Strobl J J Neurol. 2024; 272(1):86.

PMID: 39708205 DOI: 10.1007/s00415-024-12803-5.


Vision-Related Quality of Life in Patients with Systemic Lupus Erythematosus.

Bartol-Puyal F, Chacon Gonzalez M, Arias-Peso B, Garcia Navarro D, Mendez-Martinez S, Ruiz Del Tiempo M Healthcare (Basel). 2024; 12(5).

PMID: 38470651 PMC: 10931292. DOI: 10.3390/healthcare12050540.


The Patients' Perspective for the Impact of Late Detection of Ocular Diseases on Quality of Life: A Cross-Sectional Study.

Almazroa A, Almatar H, Alduhayan R, Albalawi M, Alghamdi M, Alhoshan S Clin Optom (Auckl). 2023; 15:191-204.

PMID: 37719025 PMC: 10503557. DOI: 10.2147/OPTO.S422451.

References
1.
Mangione C, Lee P, Gutierrez P, Spritzer K, Berry S, Hays R . Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001; 119(7):1050-8. DOI: 10.1001/archopht.119.7.1050. View

2.
Lamoureux E, Mitchell P, Rees G, Cheung G, Yeo I, Lee S . Impact of early and late age-related macular degeneration on vision-specific functioning. Br J Ophthalmol. 2010; 95(5):666-70. DOI: 10.1136/bjo.2010.185207. View

3.
Wong Y, Sabanayagam C, Wong C, Cheung Y, Man R, Yeo A . Six-Year Changes in Myopic Macular Degeneration in Adults of the Singapore Epidemiology of Eye Diseases Study. Invest Ophthalmol Vis Sci. 2020; 61(4):14. PMC: 7401489. DOI: 10.1167/iovs.61.4.14. View

4.
Flaxman S, Bourne R, Resnikoff S, Ackland P, Braithwaite T, Cicinelli M . Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017; 5(12):e1221-e1234. DOI: 10.1016/S2214-109X(17)30393-5. View

5.
. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98(5 Suppl):786-806. View